Advances in molecular targets and chemotherapy of tuberculosis

Drugs of Today

Volumn 40, Issue 6, 2004, Pages 487-500

  Kumari, Seema ^a   Ram, Vishnu Ji ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; GREPAFLOXACIN; ISOCITRATE LYASE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; METHYLTRANSFERASE INHIBITOR; MOXIFLOXACIN; NICKEL 2,6 DIACETYLPYRIDINEBIS(BENZOYLHYDRAZONATE); OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANOREXIA; BACTERIAL CELL WALL; BACTERIAL INFECTION; CHEMOTHERAPY; CONFUSION; DIARRHEA; DNA MICROARRAY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DYSGEUSIA; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; KIDNEY FAILURE; LIVER TOXICITY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; OPTIC NERVE DISEASE; OTOTOXICITY; REVIEW; RNA SYNTHESIS; SEIZURE; SHORT COURSE THERAPY; SIDE EFFECT; SKIN MANIFESTATION; TUBERCULOSIS; VASCULITIS; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; TUBERCULOSIS;

EID: 3242749875     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.6.850482     Document Type: Review

References (56)

1. WHO Global Tuberculosis Programme - Tuberculosis Fact Sheet, 1998 (http:/www.who.int/ gtb/publication/index.htm# Reports)
2. WHO-Country Profiles: Annual Report, Brazil 1997 (http:/www.who.int)
3. Rattan, A., Kalia, A., Ahmad, N. Multi-drug resistant Mycobacterium tuberculosis: Molecular perspectives. Emerge Infect Dis 1998, 4: 195-209.
4. Cole, S.T., Brosch, R., Parkhill, J. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393: 537-44.
5. Sensi, P., Grassi, G.G. In: Burger's Medicinal Chemistry and Drug Discovery, 5th, Vol. 2. Burger, A., Wolf, M.E. (Eds.). John Wiley & Sons, Inc., New York 1996, 575-635.
6. WHO Global Tuberculosis Programme-DOTS: Directly Observed Treatment Short-Course, 1998 (http://www.who.int/gtb/dots/index.htm)
7. Barry, C.E., III. New horizons in the treatment of tuberculosis. Biochem Pharmacol 1997, 54: 1165-72.
8. Middlebrook, G. Isoniazid resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 1994, 64: 471-2.
9. Vilchèze, C., Morbidon, H.R., Weisbrod, T.R. et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell respiratory research, Vol. 2, No. 3. In: Somoskovi et al. (Ed.). Lysis of Mycobacterium Smegmatis. J Bacteriol 2000, 182: 4059-67.
10. Slayden, R.A., Lee, R.E., Barry, C.E. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol 2000, 38: 514-25.
11. Zhang, Y., Telenti, A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Molecular Genetics of Mycobacteria. Hatful, G.F., Jacobs, W.R. Jr. (Eds.). ASM Press, Washington, DC 2000, 235-54.
12. Mitchison, D.A., Nunn, A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986, 133: 423-30.
13. Grosset, J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978, 53: 5-12.
14. Mitchison, D.A. The garrod lecture. Understanding the chemotherapy of tuberculosis: Current problems. J Antimicrob Chemother 1992, 29: 477-93.
15. Telenti, A., Imboden, P., Marches, F. et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341: 647-50.
16. Ramaswamy, S., Musser, J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc Lung Dis 1998, 79: 3-29.
17. Heep, M., Rieger, U., Beck, D., Lehn, N. Mutations in the beginning of the rpoB gene can induce resistance to rifampcins in both Helicobacter pylon and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44: 1075-7.
18. Salfinger, M., Crowle, A.J., Reller, L.B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 1990, 162: 201-7.
19. Zhang, Y., Scorpio, A., Nikaido, H., Sun, Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999, 181: 2044-9.
20. Zimhony, O., Cox, J.S., Welch, J.T., Vilcheze, C., Jacobs, W.R. Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nature Med 2000, 6: 1043-7.
21. Konno, K., Feldman, F.M., McDermont, W. Pyrazinamide susceptibility and amidase activity of the tubercle bacilli. An Rev Respir Dis 1967, 95: 461-9.
22. Scorpio, A., Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Med 1996, 2: 662-7.
23. Lin, J., Barry, C.E. III, Besra, C.S., Nikaido, H. Mycolic acid structure determines the fluidity of the mycobacterial cell wall. J Biol Chem 1996, 271: 29545-51.
24. Ajuma, I., Yamamura, Y. Studies on firmly bound lipids of human tubercle bacillus I. Isolation of arabinose mycolate. J Biochem 1962, 52: 200-6.
25. Azuma, I., Yamamura, Y. Studies on firmly bound lipids of human tubercle bacillus I. Isolation of arabinose mycolate and identification of its chemical structure. J Biochem 1963, 53: 275-81.
26. Kremer, L., Dover, L.G., Morehouse, C. et al. Galactan biosynthesis in mycobacterium tuberculosis: Identification of a bifunctional UDP-Galactofuranosyltransferase. J Biol Chem 2001, 276: 26430-40.
27. Johnson, K., Schultz, P.G. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994, 116: 7425-6.
28. Yuan, Y., Lee, R.E., Besra, G.S., Belisle, J.T., Barry, C.E. III. Identification of gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995, 92: 6630-4.
29. George, K.M., Yuan, Y., Sherman, D.R., Barry, C.R. III. The biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosios: Identification and functional analysis of CMAS-2. J Biol Chem 1995, 270: 27292-8.
30. Yuan, Y., Berry, C.E. III. A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acid in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1996, 93: 12828-33.
31. McKinny, J.D., Honer Zu Bentrup, K., Muñoz-Elias, E. et al. Persistence of mycobacteria tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406: 735-8.
32. Zahrt, Thomas C. Molecular mechanism regulating persistent Mycobacterium tuberculosis infection. Microb Infect 2003, 5: 159-67.
33. Khasnobis, S., Escuyer, V.E., Chatterjee, D. Emerging therapeutic targets in tuberculosis: Post-genomic era. Expert Opin Ther Target 2002, 6: 21-40.
34. Knox, R.J., Edwards, D.I., Knight, R.C. The mechanism of nitroimidazole damage to DNA: Coulometric evidence. Int J Radiat Oncol Biol Phys 1984, 10: 1315-8.
35. Glickman, M.S., Jacobs, W.B. Jr. Microbial pathogenesis of Mycobacterium tuberculosis down of discipline. Cell 2001, 104: 477-485.
36. Styden, R.A., Lee, R.E., Armour, J.W. et al. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis. Antimycrob Agents Chemother 1996, 40: 2813-9.
37. Chopra, P., Meena, L.S., Singh, Y. New drug targets for Mycobacterium tuberculosis. Indian J Med Res 2003, 117: 1-9.
38. Parrish, N.M., Houston, T., Jones, P.B., Townsend, C., Dick, J. In vitro activity of a novel antimycobacterial compound N-octanesulphonylacetamide and its effect on lipid and mycolic acid synthesis Antimicrob Agents Chemother 2001, 45: 1143-50.
39. Cole, S.T., Brosch, R., Parkhil, J. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393: 537-44.
40. Koul, A., Chordas, A., Tyagi, A.K., Drlica, K., Sigh, Y., Ulrich, A. Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: Characterization and localization Microbiology 2001, 147: 2307-14.
41. Glickman, M.S., Cox, J.S., Jacobs, W.R. Jr. A novel mycolic acid cyclopropane synthetase as required for cording, persistence and virulence of Mycobacterium tuberculosis. Mol Cell 2000, 5: 717-27.
42. Bohacek, R.S., McMartinn, C., Guida, W.C. The art and practice of structure-based drug design: A molecular modeling. Med Res Reviews 1996, 16, 3-50.
43. Jarvis, B., Lamb, H.M. Rifapentine. Drugs 1998, 56: 607-16.
44. Shoen, C.M., DeStefano, M.S., Cynamon, M.H. Durable cures for tuberculosis: Rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin Infect Dis 2000, 30 (Suppl. 3): S288-S290.
45. Ji, B., Lounis, N., Truffot-Pernot, C., Grosset, J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995, 39: 1341-4.
46. Fung-Tomc, J., Minassian, B., Kolek, B., Washo, T., Huczko, E., Bonner, D. In vitro antibacterial spectrum of a new broad spectrum 8-methoxy isoquinoline, gatifloxacin. J Antimicrob Chemother 200, 45: 437-46.
47. Cynamon, M.H., Klemens, S.P., Sharpe, C.A., Chase, S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43: 1189-91.
48. Stover, C.K., Warrener, P., VanDevanter, D.R. et al. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405: 962-6.
49. Lounis, N., Ji, B., Truffot-Pernot, C., Grosset, J. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 1997, 41: 607-10.
50. Ho, Y., Chan, C.Y., Cheng, A.F. In vitro activities of aminoglycosides-aminocyclitols against mycobacteria. J Antimicrob Chemother 1997, 40: 27-37.
51. Miyazaki, E., Miyazaki, M., Chen, J.M., Chaisson, R.E., Bishai, W.R. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999, 43: 85-9.
52. Schmid, P.C. Clinical experiences in cases of primary tuberculosis with tuberculostaticum isoxyl. Antibiot Chemother 1970; 16: 108-16.
53. Phetuksiri, B., Baulard, A.R., Cooper, A.M. et al. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob Agents Chemother 1999, 43: 1042-51.
54. Eustice, D.C., Feldman, G.M., Zajac, I., Slee, A.M. Mechanism of action of DuP 721: Inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988, 32: 1218-22.
55. Lin, A.H., Murray, R.W., Vidmar, T.J., Marotti, K.R. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997, 41: 2127-31.
56. Bottari, B., Maccari, R., Monforte, F. et al. Nickel (II) 2, 6-diacetylpyridine bis (isonicotinoy lhydrazonate) complexes: Structure and antimycobacterial evaluation. Part XI. Bioorg Med Chem 2001, 9: 2203-11.